Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 67

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 67
---
 number of options that are expected to vest. The total expense is recognised over the vesting period, which is the period over
which all of the specified vesting conditions are to be satisfied. Where vesting conditions are accelerated on the occurrence of a
specified event, such as a change in control or initial public offering, such remaining unvested charge is accelerated to the
income statement.

In addition, in some circumstances employees may provide services in advance of the
grant date and therefore the grant date fair value is estimated for the purposes of recognising the expense during the period between
service commencement period and grant date.

At the end of each reporting period, the Group revises its estimates of the number
of options that are expected to vest based on the non-market vesting conditions. It recognises the impact of the revision to original
estimates, if any, in the income statement, with a corresponding adjustment to equity. When the options are exercised, the Company issues
new shares. The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and
share premium.

The Group also issues warrants over ADSs to certain professional advisors in connection
with equity transactions that fall within the scope of IFRS2 and are accounted for as share based payments. The fair value of the services
received in exchange for the grant of the warrant is recognised as an expense of the equity transaction. The total expense is recognised
immediately.

Leases

Identifying Leases

The Group accounts for a contract, or a portion
of a contract, as a lease when it conveys the right to use an asset for a period of time in exchange for consideration. Leases are those
contracts that satisfy the following criteria:

(a) There is an identified asset;

(b) The Group obtains substantially all the economic
benefits from use of the asset; and

(c) The Group has the right to direct use of the
asset.

The Group considers whether the supplier has substantive
substitution rights. If the supplier does have those rights, the contract is not identified as giving rise to a lease.

In determining whether the Group obtains substantially
all the economic benefits from use of the asset, the Group considers only the economic benefits that arise from the use of the asset,
not those incidental to legal ownership or other potential benefits.

In determining whether the Group has the right
to direct use of the asset, the Group considers whether it directs how and for what purpose the asset is used throughout the period of